BUZZ - JPMorgan downgrades HubSpot rating due to "uncertain outlook" amid recovery in revenue growth
路透社2026/10/08 14:17On October 8, JPMorgan downgraded its rating for marketing software company HubSpot (HUBS.N) from “Overweight” to “Neutral,” and also lowered its price target from $268 to $240, which still represents a 23.6% upside from the previous trading day’s closing price. The report pointed out that the timeline for a recovery in revenue growth is “still unclear.” “Although HUBS shares have fallen by more than 40% so far this year, until there are clear signs that the growth slowdown has bottomed out, we do not expect to see renewed investor interest or a significant re-rating of the stock price,” said JPMorgan. Out of 37 brokerages, 13 rate the stock as “Buy” or higher, 23 as “Hold,” and 1 as “Sell”; the median price target is $250, according to Reuters compiled data. Including fluctuations on the day, the stock has declined by 45.2% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be incorrect or lack the intended context; Reuters does not guarantee the accuracy of automated translations and provides them solely for readers' convenience. Reuters assumes no liability for any damages or losses arising from the use of automated translation features.)
October 8 - ** JPMorgan downgraded marketing software company HubSpot (HUBS.N) from “Overweight” to “Neutral”
** The price target was also lowered from $268 to $240 , still implying 23.6% upside compared to the previous trading session’s closing price
** The report noted the “timeline for revenue growth recovery remains unclear”
** “Although HUBS shares have fallen more than 40% so far this year, until clear signs of a bottom in the growth slowdown emerge, we do not expect investor interest to reignite or for the stock price to see a significant re-rating”—JPMorgan
** Among 37 brokerages, 13 rate the stock as “Buy” or higher, 23 as “Hold,” and 1 as “Sell”; the median price target is $250—Reuters compiled data
** After accounting for recent volatility, the stock has declined 45.2% year-to-date
(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it merely for reader convenience. Reuters assumes no responsibility for any damage or loss caused by the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
